Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502564 | 1.00 | HTR1A (0.53) | HTR1AADRA1DADRA1AADRA1BNPC1 | |
| SCHEMBL30015078 | 0.85 | NPC1 (0.68) | HTR1AADRA1DADRA1AADRA1BNPC1 | |
| SCHEMBL2305236 | 0.85 | NPC1 (0.68) | HTR1AADRA1DADRA1AADRA1BNPC1 | |
| SCHEMBL7976948 | 0.85 | NPC1 (0.54) | HTR1AADRA1DADRA1AADRA1BNPC1 | |
| SCHEMBL9528862 | 0.83 | HTR1A (0.54) | HTR1AADRA1DADRA1AADRA1BNPC1 | |
| SCHEMBL11544509 | 0.82 | NPC1 (0.53) | NPC1RAB9ARECQLMEN1KMT2A | |
| SCHEMBL11545921 | 0.82 | NPC1 (0.68) | NPC1RAB9ARECQLMEN1KMT2A | |
| SCHEMBL23294854 | 0.82 | HTR1A (0.53) | HTR1AADRA1DADRA1AADRA1BNPC1 | |
| SCHEMBL1937817 | 0.82 | HTR1A (0.53) | HTR1AADRA1DADRA1AADRA1BNPC1 | |
| SCHEMBL7110475 | 0.82 | HTR1A (0.53) | HTR1AADRA1DADRA1AADRA1BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527272-A | Synthesis method of Tegolazan | 西安淳甄新材料有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-112358450-A | Synthesis method of 4- (benzyloxy) -2-methyl-1H-benzo [ d ] imidazole-6-carboxylic acid | 南京艾康生物科技有限公司 | 2021-02-12 | — | — | CN | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| WO-2024259303-A1 | COMPOUNDS AND COMPOSITIONS AS CEREBLON LIGANDS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-1697357-A2 | TRICYCLIC BENZIMIDAZOLES | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
| WO-2006037748-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | WO | disclosed |
| WO-2005103057-A1 | 6,7-DIHYDROXY-8-PHENYL-3,6,7,8-TETRAHYDRO-CHROMENO[7, 8-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005058893-A1 | TRICYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-5563169-A | INHIBITORS OF ACYLCOENZYME A:CHOLESTEROL TRANSFERASE, FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS | SANKYO COMPANY, LIMITED (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5446059-A | Treating or preventing inflammatory or immunoallergic conditions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-29 | — | — | US | disclosed |
| EP-0636619-A1 | TRICYCLIC HETEROCYCLIC COMPOUND | SANKYO COMPANY LIMITED (JP) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | HTR1A 3704/4885ADRA1D 2786/4885ADRA1A 3546/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HTR1A 3837/4885ADRA1D 4445/4885ADRA1A 4409/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR1A 3837/4885ADRA1D 4445/4885ADRA1A 4409/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | HTR1A 3690/4885ADRA1D 4471/4885ADRA1A 4504/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | HTR1A 1636/4885ADRA1D 3222/4885ADRA1A 3976/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | HTR1A 2758/4885ADRA1D 2193/4885ADRA1A 2676/4885 |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | HTR1A 2114/4885ADRA1D 1265/4885ADRA1A 1387/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR1A 3837/4885ADRA1D 4445/4885ADRA1A 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.